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Abstract Here we report that the Schizosaccharomyces pombe
Rad9 (SpRad9) protein contains a group of amino acids with
similarity to the Bcl-2 homology 3 death domain, which is
required for SpRad9 interaction with human Bcl-2 and apoptosis
induction in human cells. Overexpression of Bcl-2 in S. pombe
inhibits cell growth independently of rad9, but enhances
resistance of rad9-null cells to methyl methanesulfonate, ultra-
violet and ionizing radiation. These observations suggest that
SpRad9 may represent the first member of the Bcl-2 protein
family identified in yeast, though the cell death pathways in
S. pombe may differ from those found in mammals. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
The Bcl-2 family of proteins controls a distal step in an
evolutionarily conserved pathway for programmed cell death
[1^4]. Some proteins within this family, including Bcl-2 and
Bcl-xL, function as suppressors of apoptosis, whereas others,
such as Bax and Bad, act as promoters of cell death. Bcl-2
family proteins share conserved regions, termed Bcl-2 homol-
ogy (BH) domains: BH1, BH2, BH3 and BH4, which can be
important for the interactions between Bcl-2 family members
and for their function [2]. The BH1 and BH2 domains of the
anti-apoptotic proteins such as Bcl-2 and Bcl-xL and the BH3
domain of the pro-apoptotic proteins such as Bax and Bak
appear to be essential for homo- and heterodimerization be-
tween the Bcl-2 family members [5^7]. In addition, several
proteins, including Bik, Bim, Bid, Hrk, Bad and nematode
Egl-1, contain only the BH3 domain and promote apoptosis,
thus constituting a new category called the BH3-only subfam-
ily of the Bcl-2 family [2,8]. Most of these BH3-only proteins
can form heterodimers with anti-apoptotic Bcl-2 family mem-
bers such as Bcl-2 and Bcl-xL and inhibit their cell survival
activity.
Recently, apoptosis-like features have been observed in
some unicellular organisms and non-metazoan multicellular
eukaryotes [9^13]. The human Bcl-2 protein can protect
some mutant yeast from cell death caused by oxidative injury
[14]. Moreover, as in mammalian cells, expression of pro-ap-
optotic Bcl-2 family proteins Bax and Bak in the yeasts Sac-
charomyces cerevisiae and Schizosaccharomyces pombe induces
cell death that can be suppressed by anti-apoptotic Bcl-2 fam-
ily proteins, including Bcl-2 and Bcl-xL [15^19]. These ¢ndings
imply that the cell suicide pathway controlled by the Bcl-2
family of proteins in mammalian cells may have very primitive
evolutionary origins.
We have previously reported that the human homologue of
S. pombe Rad9 (SpRad9), which is involved in the control of
cell cycle checkpoints, contains a BH3 domain, and promotes
apoptosis by binding to and inhibiting Bcl-2 and Bcl-xL in
cells [20]. Here, we show that SpRad9 can also interact with
Bcl-2, and induce apoptosis in mammalian cells through a
region similar to the BH3 domain, thus providing evidence
that the Bcl-2 family of proteins may be evolutionarily con-
served from ¢ssion yeast to human.
2. Materials and methods
2.1. Plasmids
S. pombe rad9 cDNA [21,22] was employed as template for the
polymerase chain reactions (PCR) to amplify DNA. Mutations were
created using a two-step PCR method [23]. The rad9 DNA fragments
with engineered EcoRI and XhoI sites were cloned in frame into the
EcoRI/XhoI-digested yeast two-hybrid vectors pGilda and pJG4-5
[24], or the EcoRI/SalI-digested FLAG-tag vector pFLAG-CMV2
[24]. The cDNA fragments encoding green £uorescence protein
(GFP) and human Bcl-2 were blunt-ended and subcloned into the
NdeI-digested/blunted pREP41 (LEU2 marker) vector, which contains
a thiamine repressible nmt promoter for conditional expression in
S. pombe [25]. All other plasmids have been described [20].
2.2. Yeast strains and media
S. pombe SP223 (h3 leu1-32 ade6-162 ura4) and the isogenic
rad9: :ura4 derivative were cultured in YEA media [21]. S. pombe
transformations were performed using the lithium acetate method
[26], and cultured in pombe medium (PM) lacking leucine to select
cells retaining plasmids [21].
2.3. Analysis of S. pombe cell growth and sensitivity to DNA-damaging
agents
Transformants were grown in PM medium containing thiamine
(5 Wg/ml) overnight, then washed three times with water. Cultures
were diluted to a ¢nal concentration of 5U105 cells/ml in fresh PM
medium with or without thiamine, to either repress or induce, respec-
tively, the nmt promoter in the pREP41 plasmid, and cultured over-
night. Cells were again diluted to 5U105 cells/ml and cultured in fresh
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PM medium with or without thiamine, and the number of cells was
determined at various times by using a hemocytometer. For DNA
damage assays, the twice diluted cells were grown overnight in PM
medium with or without thiamine to mid-log phase, then treated with
ultraviolet (UV) light, Q-rays or 0.5% methyl methanesulfonate
(MMS). The percentage of viability was calculated as the numbers
of colonies formed relative to mock-treated controls.
3. Results
3.1. SpRad9 interacts with Bcl-2 in a BH3-like
domain-dependent manner
Sequence comparisons revealed that SpRad9 (accession
number X64648), like human Rad9, contains a group of
15 amino acids (16IFTNLSRIDDAVNWE30) with homology
to the BH3 domains of pro-apoptotic Bcl-2 family proteins
[20]. Initially, yeast two-hybrid assays were employed to test
the ability of SpRad9 to interact with Bcl-2 family proteins.
This test indicated that SpRad9, whether fused to the trans-
activation or binding domain, strongly interacted with Bcl-2,
to a degree comparable with the interactions between Bcl-2
and Bax, as demonstrated by a quantitative o-nitrophenyl
L-galactoside (ONPG) assay (Fig. 1A). In contrast,
SpRad9vBH3, a deletion mutant of Rad9 protein lacking
critical residues in the BH3-like region (amino acids 20^27),
failed to form two-hybrid interactions with Bcl-2. The specif-
icity of the association between Bcl-2 and SpRad9 was con-
¢rmed by the failure of these proteins to form two-hybrid
interactions with Bax or v-Ras.
To determine whether similar interactions could occur be-
tween SpRad9 and Bcl-2 in mammalian cells, human 293T
epithelial cells were transiently co-transfected with plasmids
encoding Bcl-2 and FLAG-epitope tagged full-length SpRad9
or SpRad9vBH3. Immunoprecipitations were performed with
anti-FLAG or anti-Myc antibody as a control, followed by
an SDS^PAGE immunoblot assay using antisera speci¢c
for SpRad9 or Bcl-2. Under these conditions, Bcl-2 could
be coimmunoprecipitated with the wild-type SpRad9 pro-
Fig. 1. SpRad9 interaction with Bcl-2 is dependent on the BH3-like
domain. (A) Strain EGY48 S. cerevisiae cells were co-transformed
with various pGilda expression plasmids encoding LexA DNA-bind-
ing domain fusion proteins in combination with various pJG4-5
plasmids that produce B42 transactivation domain fusion proteins
[38]. The strength of protein^protein interactions was determined by
the quantitative ONPG assay [39]. Immunoblotting with polyclonal
rabbit antisera speci¢c for SpRad9 con¢rmed expression of all dele-
tion mutants that failed to interact with Bcl-2 (not shown). (B)
293T cells were transiently co-transfected with pRC/CMV-Bcl-2 and
pFLAG-CMV2 plasmids encoding SpRad9 or SpRad9vBH3 mutant
proteins. Two days after transfection, immunoprecipitations were
performed as described [20] using either anti-Myc antibody as a
negative control or anti-FLAG M2 antibody followed by immuno-
blot analysis of the resulting immune complex using either anti-
SpRad9 (top) or anti-Bcl-2 (middle) polyclonal antisera. In addition
to immune complexes, 25 Wg of the cell lysates was analyzed directly
(bottom).
Fig. 2. Overexpression of SpRad9 kills human cells. (A) 293T cells
in 6-well plates were transiently co-transfected by a calcium-phos-
phate precipitation method with 1 Wg of pFLAG-CMV2 encoding
SpRad9 or SpRad9vBH3 and 1 Wg of pcDNA3-Bcl-2, pcDNA3-Bcl-
xL or parental plasmid DNA, together with 0.2 Wg of pCMV-L-gal
plasmid as a marker for transfected cells. The total amount of plas-
mid DNA was normalized to 2.2 Wg for each transfection by adding
control vector pcDNA3. 24 h after transfection, £oating and adher-
ent cells were ¢xed with 2% formaldehyde and stained with X-gal
as described [20]. The percentage of transfected cells (blue) with ap-
optotic morphology (round dark blue) was determined (data shown
are means þ S.D.; n = 3). (B) MCF7 cells were transfected with the
control vector pEGFP-C2 (GFP), or pEGFP-C2 encoding SpRad9
or the SpRad9vBH3 mutant proteins by lipofectin (Gibco BRL)
and selected in 400 Wg/ml G418. Neomycin-resistant cells were cul-
tured without fetal calf serum for various times, and the percentage
of viable cells was determined by exclusion of trypan blue dye (data
shown are means þ S.D.; n = 3).
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tein (Fig. 1B). In contrast, the BH3 deletion mutant
(SpRad9vBH3) failed to coimmunoprecipitate with Bcl-2; im-
munoblot analysis con¢rmed the presence of the Bcl-2 protein
in the cell lysates. Taken together, these ¢ndings indicate that
Bcl-2 associates with SpRad9 and that the BH3-like region of
SpRad9 is required for this interaction.
3.2. SpRad9 induces human cell death only when the BH3-like
domain is intact
To elucidate the e¡ects of SpRad9 on cell death, we tran-
siently transfected FLAG-tagged SpRad9 into 293T cells to-
gether with a lacZ reporter plasmid. 24 h after transfection,
nearly 60% of the cells transfected with SpRad9-expressing
plasmid died, compared to V30% of the cells receiving the
Neo control plasmid (Fig. 2A). Co-expression of Bcl-2 or Bcl-
xL essentially abrogated the e¡ects of SpRad9 on cell death.
In contrast to the wild-type SpRad9 protein, removal of the
BH3-like region dramatically reduced the ability of SpRad9 to
induce cell death.
Next, we con¢rmed that the pro-apoptotic activity of
SpRad9 was not unique to 293T cells by introducing a
GFP-tagged SpRad9 into MCF7 human mammary carcinoma
cells. Cells that received the GFP-SpRad9 plasmids died faster
compared to the control GFP-transfected cells when deprived
of serum from the cultures (Fig. 2B). In the experiment
shown, for example, half of the cells expressing GFP-SpRad9
died from apoptosis after serum withdrawal for 1 day, com-
pared to V20% of the MCF7-GFP control cells. In contrast,
expression of the deletion mutant GFP-SpRad9vBH3 protein
has no e¡ect on the viability of MCF7 cells and the kinetics of
cell death were essentially the same as in the control cells
expressing GFP alone.
To date, we have been unable to generate any stable cell
lines derived from FL5.12, Jurkat, HeLa and NIH3T3 that
express the SpRad9 transgene at high levels in the absence of
exogenous Bcl-2 or Bcl-xL, providing evidence that overex-
pression of SpRad9 is also lethal to these cells (not shown).
3.3. Bcl-2 enhances resistance of rad9-null S. pombe cells to
DNA-damaging agents
It has been reported that the human Bcl-2 protein can pro-
Fig. 3. Bcl-2 rescues rad9: :ura4 S. pombe cells from DNA dam-
age. S. pombe strains rad9 and rad9: :ura4 were transformed with
pREP41 plasmids encoding the human Bcl-2 protein or GFP as a
control. Transformants were grown in selective medium with (+) or
without (3) thiamine to either repress or induce, respectively, the
nmt promoter. Exponentially growing cells were exposed to 0.5%
MMS for various times (A), or UV light (B) or Q-rays (C) at the in-
dicated doses. An equal number of cells were plated on PM mini-
mal media lacking leucine and containing thiamine, and viability
was assayed by the ability to form colonies relative to mock-treated
cells (data shown are means þ S.D.; n = 3). Symbols represent:
(a), rad9/bcl-2+thiamine; (b), rad9/bcl-23thiamine; (E), rad9/
gfp+thiamine; (F), rad9/gfp3thiamine; (O), rad9: :ura4/bcl-2+thi-
amine; (R), rad9: :ura4/bcl-23thiamine; (7), rad9: :ura4/gfp+thi-
amine; and (8), rad9: :ura4/gfp3thiamine.
Fig. 4. Bcl-2 inhibits cell growth of S. pombe. Cells were trans-
formed and grown as described in Fig. 3. The rates of cell growth
were determined by counting the number of cells using a hemocy-
tometer during a 24 h period.
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tect some mutant strains of budding yeast that lacked super-
oxide dismutase from cell death induced by oxidative stress
[14]. SpRad9 is essential for the resistance of S. pombe to
Q-rays and UV light [21,27]. To determine whether Bcl-2
also protects rad9 de¢cient ¢ssion yeast cells from the geno-
toxic e¡ects of DNA-damaging agents, we introduced the hu-
man bcl-2 gene or gfp as a control into rad9 and rad9: :ura4
S. pombe strains under the regulation of a thiamine repressible
nmt promoter for conditional expression. Transformants were
exponentially cultured in PM medium with or without thi-
amine, to either repress or induce, respectively, expression of
the transgenes, and treated with MMS, UV or radiation. As
shown in Fig. 3, expression of Bcl-2 signi¢cantly increased the
resistance of rad9: :ura4 cells to cell death induced by MMS,
UV and Q-rays, compared to the cells expressing the GFP
control protein. In contrast, there are no di¡erences in the
sensitivity pro¢les of transformants containing the Bcl-2 or
control plasmids when grown in thiamine-supplemented me-
dium. However, the human Bcl-2 protein has no e¡ect on the
survival of rad9 S. pombe cells exposed to these DNA-dam-
aging agents. When treated with MMS, UV or Q-rays, the
rad9 S. pombe transformants showed similar viability in me-
dium containing or devoid of thiamine.
3.4. Bcl-2 inhibits cell growth in both rad9+ and
rad9: :ura4+ strains
It has been reported that overexpression of the anti-apopto-
tic Bcl-2 protein causes human cells to delay entry into the S
phase of the cell cycle [28^31], but the biochemical mechanism
is unclear. We therefore employed ¢ssion yeast as a model to
examine whether Bcl-2 can also inhibit S. pombe cell growth
and, if so, whether the interaction of Bcl-2 with Rad9 is nec-
essary. Both rad9 and rad9: :ura4 S. pombe cells were trans-
formed with conditional expression plasmids encoding the
human Bcl-2 protein or GFP as a control, and cultured in
growth media in the presence or absence of thiamine. Induc-
tion of Bcl-2 expression markedly inhibited cell growth in
both rad9 and rad9: :ura4 cells, suggesting that the rad9
gene is not essential for Bcl-2 to inhibit cell growth in this
yeast (Fig. 4). In contrast, expression of the control GFP
protein did not in£uence the rates of cell growth in both
rad9 and rad9: :ura4 ¢ssion yeast cells. Growth of the
GFP-carrying but non-expressing cells was the same as for
the other cells not expressing their respective transgenes (not
shown).
4. Discussion
The ¢ndings reported here suggest that SpRad9 may be a
member of the BH3-only family of apoptosis promoting pro-
teins. Like human Rad9, SpRad9 also contains a region near
its N-terminus (amino acids 16^30) with similarity to the BH3
domains of pro-apoptotic Bcl-2 family proteins, but lacks
critical residues found in BH1, BH2 and BH4. Overproduc-
tion of this ¢ssion yeast protein in human cells induced cell
death, which can be blocked by co-expression of Bcl-2 or Bcl-
xL. Deletion of the BH3-like region from SpRad9 abolished
its ability to interact with Bcl-2 and to induce apoptosis in
human cells, consistent with properties of other members of
the BH3-only pro-apoptotic protein family [2,8,20]. These
proteins are unable to form homodimers but can heterodimer-
ize with anti-apoptotic members of the Bcl-2 family and an-
tagonize their function. One mechanism by which the BH3-
only proteins may induce apoptosis could involve competitive
displacement of a pro-apoptotic partner such as Bax or Apaf-
1 from a complex with death antagonists of the Bcl-2 family,
freeing it to commit the cell to apoptotic suicide [2,8].
Cell cycle checkpoints control cell cycle progression, allow-
ing more time, for example, to repair damaged DNA prior to
progression into the S or G2 phases of the cell cycle. In multi-
cellular organisms, checkpoints play an essential role in main-
tenance of genomic integrity. To prevent genetic diseases and
cancer, the mutated or damaged cells must be eliminated
through activation of a physiological process (apoptosis). In
relatively simple organisms, checkpoint controls are critical
for survival when exposed to DNA-damaging agents or
DNA replication inhibitors. S. pombe rad9 is one of six check-
point genes in ¢ssion yeast, and plays an essential role in
mediating resistance to radiation [21,32]. The rad9 mutant
strains of S. pombe, which are unable to stop cell cycle pro-
gression in response to DNA damage, are more sensitive to
Q-rays, UV light or MMS compared to rad9 cells. These
results are not consistent with those found in human cells,
in which expression of an antisense Rad9 RNA blocks apo-
ptosis induced by MMS, suggesting that this organism may
use di¡erent machinery to control cell cycle progression and
cell death processes in response to DNA damage. In mam-
mals, Rad9 may contribute more to activation of apoptosis
than to arrest of the cell cycle after DNA damage. In addi-
tion, other pathways controlling cell cycle checkpoints, which
are Rad9-independent, may exist in humans. In ¢ssion yeast,
however, the inability to delay cell cycle progression after
radiation-induced DNA damage accounts for an essential
part of the radiosensitivity of rad9 mutant cells, though the
lack of other cell cycle-independent functions of Rad9 may
also contribute [27].
It has been suggested that cell suicide mechanisms may exist
even in unicellular organisms [11,33], potentially limiting rep-
lication of viruses, reducing competition for nutrients during
periods of starvation, or eliminating cells with damaged or
mutated DNA to keep up the genomic integrity of future
generations. Though apoptosis-like cell death has been ob-
served in several unicellular eukaryotes [10,11,34^36], the spe-
ci¢c cell death machinery may di¡er from that found in multi-
cellular organisms. Our results that expression of Bcl-2 can
partially enhance resistance of rad9 mutant S. pombe cells to
DNA-damaging agents, however, argue that the cell death
pathway controlled by the Bcl-2 family is, at least in part,
conserved in yeasts.
In addition to the control of apoptosis, it has been demon-
strated that Bcl-2 family proteins can also modulate cell cycle
progression. Overexpression of Bcl-2 or Bcl-xL causes cells to
delay entry into S phase [28^31], while production of the pro-
apoptotic protein Bax increased the proportion of cells in this
phase of the cell cycle [37]. Interestingly, expression of the
human Bcl-2 protein in ¢ssion yeast inhibits cell growth,
although that is Rad9-independent. The potential for Bcl-2
to modulate the cell cycle, causing a slowing of either entry
into (G0 to G1) or progression through the cell cycle, may
explain, at least in part, why expression of Bcl-2 can protect
S. pombe cells from genotoxic e¡ects of DNA-damaging
agents. Clearly, further studies are required to explore the
biochemical mechanism by which Rad9 commits the cell to
undergo suicide or DNA repair.
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